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Abstract
Introduction: In the past, no effective systemic therapy has existed for patients with advanced hepatocellular
carcinoma. Sorafenib, an oral multikinase inhibitor, has recently been shown to improve overall survival in patients
with advanced hepatocellular carcinoma in two randomized, double-blinded, placebo-controlled trials. This drug
has been approved as the first-line therapy for advanced hepatocellular carcinoma patients. We report an
intriguing case of advanced hepatocellular carcinoma in which the patient achieved late- onset partial response by
prolonged administration of sorafenib in spite of progressive disease.
Case presentation: A 54-year-old Japanese man was treated with sorafenib for multiple lung metastases after surgical
resection for advanced hepatocellular carcinoma accompanied by vascular invasion of the left branch of the portal vein.
Although the effective diagnosis was progressive disease, almost all sites began to reduce or disappear eight months
after the diagnosis of progressive disease. A dramatic reduction in alpha-fetoprotein and des-gamma-carboxy
prothrombin levels was observed. The patient finally achieved partial response and his status remains unchanged.
Conclusions: If tolerated, prolonged sorafenib treatment may be beneficial.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cause of malignancies worldwide and represents
the third most common cause of cancer-related death
[1]. HCC frequently recurs despite curative local control
such as surgical resection or local ablation therapy and
the prognosis of patients with advanced HCC including
invasion to intrahepatic large vessels remains dismal
[2-5]. No systemic therapies in a meta-analysis were
shown to confer a survival advantage over best-suppor-
tive care [6]. Recently, sorafenib (Nexavar
®, Bayer
HealthCare Pharmaceuticals), an oral multikinase inhibi-
tor that mainly targets Raf kinases, vascular endothelial
growth factor receptors 1, 2, and 3, and platelet-derived
growth factor receptor beta, has been shown to improve
overall survival in patients with advanced HCC in two
randomized, double-blinded, placebo-controlled trials
[7,8]. This drug has been approved as the first-line ther-
apy for these patients.
The tumor response and its clinical course observed
under treatment with sorafenib are rather different from
the other conventional cytotoxic agents. In fact, most of
the patients who responded to sorafenib had stable dis-
ease (SD) in both of these studies [7,8], and sorafenib
seldom induces the dimensional tumor shrinking usually
observed with conventional cytotoxic agents. Therefore,
it has been suggested that sorafenib prolongs survival by
delaying disease progression.
We report the case of a patient with advanced HCC
who showed an intriguing clinical course. The patient
achieved late- onset partial response (PR) by continuing
sorafenib in spite of the progressive disease (PD).
Case presentation
At the end of 2008, a 54-year-old Japanese man was
referred to our hospital because a liver mass had been
discovered by ultrasonographic examination. Enhanced
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15 cm in diameter extending from the left lobe to the
anterior segment of the right lobe, which was enhanced
in the arterial phase and washed out in the equilibrium
phase, which is typical of HCC (Figure 1). The left
branch of the portal vein was not identified as being
involved in the tumor. Extrahepatic metastasis was not
observed. The patient was in good health, and his East-
ern Cooperative Oncology Group performance status
was 0. He had never smoked cigarettes, drunk alcohol,
or been diagnosed as obese or diabetic. Laboratory data
demonstrated normal liver function and he had no evi-
dence of past or persistent hepatitis B virus or hepatitis
C virus infection. Elevations of alpha-fetoprotein (AFP)
and des-gamma-carboxy prothrombin (DCP) levels were
observed: AFP level 119 ng/ml (normal range < 10);
DCP level 158,000 mAU/ml (normal range < 40). His
Child-Pugh score was A 5, and the tumor stage was
Barcelona Clinic Liver Cancer stage C. According to the
clinical practice guidelines for HCC [9], surgical resec-
tion was considered because of normal underlying liver,
although it was accompanied by vascular invasion. Sub-
sequently, an extended left lobectomy was performed,
and complete resection of the tumorous area was
achieved. The pathological examination confirmed a
moderate differentiated HCC with portal vein invasion
of the left branch, and the underlying liver tissues were
normal.
Eight months after the resection, recurrence of multi-
ple lung metastases was detected on a follow-up periodi-
cal CT scan. Intrahepatic recurrence was not observed.
The patient was initially treated with sorafenib at 800
mg per day. Two weeks later, a grade-2, hand-foot skin
reaction occurred and a dose reduction of 400 mg per
day was made. After two months, follow-up CT scans
showed a growth and new metastatic lesions in the lung
and liver, and PD was diagnosed according to the
revised Response Evaluation Criteria in Solid Tumors
Guidelines (RECIST 1.1) and modified RECIST [10,11].
After the diagnosis of PD, the patient participated in a
randomized, double-blind, placebo-controlled, compara-
tive study of S-1 (TS-1, Taiho Pharmaceutical Co., Ltd.,
Tokyo, Japan) of an oral cytotoxic anti-cancer agent.
Response evaluation after the first cycle was PD, and the
treatment was discontinued. Sorafenib 400 mg per day
was started again based on a consensus for the retreat-
ment. Metastatic lesions continued to worsen over six
months despite the retreatment with sorafenib (Figure 2
A1-3, B1-3); however, almost all lesions began to shrink
or disappear eight months after restarting sorafenib.
Dramatic reductions in AFP and DCP levels (AFP
decreased from 3640 ng/ml to 263 ng/ml, and DCP
from 3080 mAU/ml to 272 mAU/ml) were observed. PR
was observed on the CT scan (Figure 2C1-3), and the
patient remains stable on sorafenib at a dose of 400 mg
per day. Currently, he is working full time and is in
excellent general health.
Discussion
Our patient achieved PR after 10 months beyond PD
during long-term treatment with sorafenib. Generally,
the withdrawal of molecular targeted agents including
sorafenib, for a diagnosis of PD, is followed by a con-
ventional criterion of cytotoxic anti-cancer agents. How-
ever, in the present case, treatment with sorafenib was
continued based on the patient’s tolerability and strong
AB
Figure 1 Contrast-enhanced computed tomography scans before surgical resection. (A) Arterial phase showed a large hypervascular lesion
extending from the left lobe to the anterior segment of the right lobe. (B) The left branch of the portal vein was not identified as being
involved in the tumor, invasion of the portal vein was suspicious (white arrow).
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therapy option was available. This case showed that the
manner of treatment with sorafenib, differing from the
standard treatment criterion, could induce the treatment
response to PR. To the best of our knowledge, this is
the first report in the literature of late-onset response of
sorafenib beyond PD in patients with advanced HCC.
The underlying mechanism of late-onset tumor shrink-
age beyond PD is unclear. One could hypothesize that
the mainstream signaling pathway of the tumor involved
in cell proliferation or angiogenesis might change to
b e c o m em o r es e n s i t i v eb ym u t a t i o no rs o m eo t h e r
alteration by prolonged administration. Retreatment
with sorafenib after the first PD might be related to the
C1
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Figure 2 (A1-3) Contrast-enhanced computed tomography scans before restarting sorafenib. (A1, 2) Multiple metastatic lesions were
observed in the lung (black arrows). (A3) Local tumor progressions were also observed in the cut surface of the liver (white arrows). (B1-3)
Contrast-enhanced computed tomography scans six months after restarting sorafenib. (B1) The growth and new metastatic lesions were
observed in the lung (black arrows). (B2) In addition, mediastinal lymph node metastases were observed anew (white arrows). (B3) Local tumor
progressions were unequivocally observed (white arrows). (C1-3) Contrast-enhanced computed tomography scans 10 months after
restarting sorafenib. (C1) Metastatic lesions in the lung shrunk or disappeared (black arrows). (C2-3) Mediastinal lymph node metastases and
local tumor progressions completely disappeared (white arrows).
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that tumor cell necrosis was enhanced by re-exposure to
sorafenib in a study of renal cell carcinoma (RCC) xeno-
graft models [12].
The anti-tumor response of molecular targeted agents
including sorafenib seems to be different from that of
the conventional cytotoxic agents because a specific
response manner has been observed. For instance,
approximately 70% of patients showed SD with a lower
response rate (2%) in initial phase III studies of sorafe-
nib [7]. On the other hand, rapid regression after a
short period of only one or two weeks of treatment with
sorafenib has been reported [13]. Several patients
achieved PR after approximately 10 months of SD in
patients with sorafenib for metastatic RCC [14]. These
findings suggest that sorafenib could induce efficacy and
clinical benefit by various methods of treatment and
that molecular-targeted agents have a more complicated
responsiveness than do cytotoxic agents. Therefore, we
s u g g e s tt h a tt h e r em i g h to c c a s i o n a l l yb er e s p o n d e r s ,o n
long-term administration ofs o r a f e n i b ,a m o n gt h eP D
cases. Further studies are required to determine factors
underlying clinical outcome.
Conclusion
If tolerated, prolonged sorafenib treatment may be bene-
ficial. The efficacy of sorafenib on a long-term basis
warrants further investigation because molecular tar-
geted agents deliver a potent impact of various cellular
signal transductions.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
Authors’ contributions
YO gathered the information for this case and was a major contributor in
writing the manuscript. TN contributed in writing the Discussion and editing
the manuscript. HH, AS and WK contributed to the writing of the
manuscript. All authors read and approved the final version of the
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 September 2011 Accepted: 26 January 2012
Published: 26 January 2012
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA
Cancer J Clin 2005, 55:74-108.
2. Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H,
Tsuchihashi T, Saigenji K: Radiofrequency ablation of hepatocellular
carcinoma: correlation between local tumor progression after ablation
and ablative margin. AJR Am J Roentgenol 2007, 188:480-488.
3. Nakazawa T, Adachi S, Kitano M, Isobe Y, Kokubu S, Hidaka H, Ono K,
Okuwaki Y, Watanabe M, Shibuya A, Saigenji K: Potential prognostic
benefits of radiotherapy as an initial treatment for patients with
unresectable advanced hepatocellular carcinoma with invasion to
intrahepatic large vessels. Oncology 2007, 73:90-97.
4. Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M,
Kokubu S, Saigenji K: Intrahepatic distant recurrence after radiofrequency
ablation for a single small hepatocellular carcinoma: risk factors and
patterns. J Gastroenterol 2008, 43:71-78.
5. Okuwaki Y, Nakazawa T, Kokubu S, Hidaka H, Tanaka Y, Takada J,
Watanabe M, Shibuya A, Minamino T, Saigenji K: Repeat radiofrequency
ablation provides survival benefit in patients with intrahepatic distant
recurrence of hepatocellular carcinoma. Am J Gastroenterol 2009,
104:2747-2753.
6. Lopez PM, Villanueva A, Llovet JM: Systematic review: evidence-based
management of hepatocellular carcinoma–an updated analysis of
randomized controlled trials. Aliment Pharmacol Ther 2006, 23:1535-1547.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC,
Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L,
Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M,
Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sorafenib
in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
8. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S,
Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K,
Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in
the Asia-Pacific region with advanced hepatocellular carcinoma: a phase
III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009,
10:25-34.
9. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S,
Matsuyama Y, Okazaki M, Okita K, Omata M, Saida Y, Takayama T,
Yamaoka Y: Development of evidence-based clinical guidelines for the
diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol
Res 2008, 38:37-51.
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,
Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L,
Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid
tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009,
45:228-247.
11. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for
hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60.
12. Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D,
Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW,
Goldberg SN, Bhatt RS: Resistance of renal cell carcinoma to sorafenib is
mediated by potentially reversible gene expression. PLoS One 2011, 6:
e19144.
13. Nakazawa T, Hidaka H, Shibuya A, Koizumi W: Rapid regression of
advanced hepatocellular carcinoma associated with elevation of des-
gamma-carboxy prothrombin after short-term treatment with sorafenib
- a report of two cases. Case Rep Oncol 2010, 3:298-303.
14. Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H: Overall survival and
good tolerability of long-term use of sorafenib after cytokine treatment:
final results of a phase II trial of sorafenib in Japanese patients with
metastatic renal cell carcinoma. BJU Int 2011, 108:1813-1819.
doi:10.1186/1752-1947-6-38
Cite this article as: Okuwaki et al.: Late-onset benefit in progressive
advanced hepatocellular carcinoma with continued sorafenib therapy: a
case report. Journal of Medical Case Reports 2012 6:38.
Okuwaki et al. Journal of Medical Case Reports 2012, 6:38
http://www.jmedicalcasereports.com/content/6/1/38
Page 4 of 4